ARTICLE | Clinical News
ALG889: Began Phase I trial
December 4, 2000 8:00 AM UTC
Allergene Inc., San Mateo, Calif. Product: ALG889 Business: Infectious diseases Therapeutic category: Immune modulation Target: T cells Description: T cell receptor peptide immunomodulator Indicatio...